We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
NATEGLINIDE FOR DIABETIC PATIENTS WITH LIVER CIRRHOSIS.
- Authors
Jang, H. W.; Hong, W. J.; Kim, M. K.; Jeong, I. S.; Kim, K. S.; Kim, H. J.; Ku, B. J.
- Abstract
Purpose. About 30% of patients with liver cirrhosis have diabetes. Postprandial hyperglycemia is more problematic than fasting hyperglycemia when managing diabetic patients with cirrhosis. Nateglinide decreases in the mealtime plasma glucose levels. The present study aims to determine whether nateglinide is suitable for the management of diabetic patients with liver cirrhosis. Methods. This was a retrospective analysis of the cirrhotic patients who were treated at CNUH between Jan 2003 and Dec 2009. A total of 81 Child-Pugh Class A or B patients who had been treated with insulin (I, n=27) or nateglinide (N, n=27) for at least 12 months were included in the study, while 27 cirrhotic patients without diabetes (C, n=27) were included as a control group. We compared the efficacy of treatment and the safety between the groups. Results. The basal mean HbA1c level was higher in the insulin treatment group than that in the nateglinide treatment group. The mean HbA1c was lowered in the patients treated with insulin (9.36 ± 1.71% → 7.69±1.52%, p=0.026), but this was not changed in the patients treated with nateglinide (8.01±2.37 % →7.78±2.11%, p=0.692) after 12 months treatment. There was no change in the Child-Pugh score in all the groups. Conclusion. In case of mild hyperglycemia, nateglinide may be used for glycemic control in diabetic patients with cirrhosis as an insulin substitute without worsening the state of liver cirrhosis.
- Subjects
PEOPLE with diabetes; CIRRHOSIS of the liver; HYPERGLYCEMIA; INSULIN; DIAGNOSIS of diabetes; GLYCOGENOLYSIS
- Publication
Acta Endocrinologica (1841-0987), 2011, Vol 7, Issue 2, p229
- ISSN
1841-0987
- Publication type
Article
- DOI
10.4183/aeb.2011.229